India testing patient India

Diagnostic firms’ valuations get pricey amid health fears

www.livemint.com

₹1,029 in Q3. For Dr Lal, realization per patient in Q3FY21 stood at ₹824 ( ₹688 in Q3FY20). These firms are also de-risking business models by expanding in new geographies.The firms are expected to report good numbers in Q4, too.

Edelweiss Securities Ltd expects Dr Lal’s top-line to increase 36% y-o-y driven by non-covid testing (up 23%), higher realizations (up 7%) and additional business from covid-19 and allied testing.For Thyrocare, they expect revenue to grow 45% y-o-y led by similar factors.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News